ReviewPhysics and imaging in radiation oncology2025
FAPI-positron emission tomography for radiotherapy in head and neck cancer: applications and future directions.
Review in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maintaining quality of scientific peer-review and publishing inPhysics and imaging in radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is a cornerstone in the treatment of head and neck squamous cell carcinoma (HNSCC). Imaging plays an important role in target delineation in order to achieve adequate target dose and on the other hand limit radiation-induced toxicity to surrounding healthy tissues. Advancements in imaging techniques, including functional imaging with positron emission tomography (PET), have improved accurate target delineation, allowed for adaptive radiotherapy, and improved response evaluation. This review explores the potential role of fibroblast activation protein inhibitor (FAPI)-PET/CT in radiotherapy planning for HNSCC, comparing its efficacy to the current standard, fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT. FAPI-PET/CT is an emerging imaging modality that for pretreatment imaging may increase lesion detection, especially near the skull base. For target delineation FAPI PET/CT may enhance the specificity of tumor delineation, particularly in distinguishing tumor tissue from normal tissue. Current evidence suggests that FAPI-PET increases the GTV volume, but whether this represents more accurate tumor delineation or overestimation remains unclear. For response monitoring after treatment, there is no evidence in head and neck cancer, but for rectal cancer FAPI-PET/CT showed promising results in detection of residual disease after neo-adjuvant radiotherapy. For now, FAPI-PET/CT could be used as additional imaging, and should not be used as replacement for other imaging modalities. There is an urgent need for prospective validation studies to determine the clinical impact of FAPI-PET on radiotherapy planning and response monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.